Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

NCT00790335 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 692

Last updated 2018-03-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic syndrome(PTS)in patients with symptomatic proximal deep vein thrombosis(DVT)as compared with optimal standard DVT therapy alone.

Conditions

  • Deep Vein Thrombosis
  • Venous Thrombosis
  • Postphlebitic Syndrome
  • Venous Thromboembolism
  • Post Thrombotic Syndrome

Interventions

DRUG

Recombinant tissue plasminogen activator (rt-PA)

Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.

Sponsors & Collaborators

  • McMaster University

    collaborator OTHER
  • Ontario Clinical Oncology Group (OCOG)

    collaborator OTHER
  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH
  • BSN Medical Inc

    collaborator INDUSTRY
  • Genentech, Inc.

    collaborator INDUSTRY
  • Medtronic - MITG

    collaborator INDUSTRY
  • Boston Scientific Corporation

    collaborator INDUSTRY
  • Mid America Heart Institute

    collaborator OTHER
  • Society of Interventional Radiology Foundation

    collaborator OTHER
  • Massachusetts General Hospital

    collaborator OTHER
  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Suresh Vedantham, M.D. · Clinical Coordinating Center at Washington University School of Medicine

  • Clive Kearon, MB, MRCP, FRCP(C), PhD · Data Coordinating Center at McMaster University-Ontario Clinical Oncology Group

  • Samuel Z Goldhaber, M.D. · Brigham and Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00790335 on ClinicalTrials.gov